Abstract
Earlier studies have demonstrated an unexplained depletion of the epidermal growth factor receptor (EGFR) protein expression in prostatic cancer. We now attribute this phenomenon to the presence of a variant EGFR (EGFRvIII) that is highly expressed in malignant prostatic neoplasms. In a retrospective study, normal, benign hyperplastic and malignant prostatic tissues were examined at the mRNA and protein levels for the presence of this mutant receptor. The results demonstrated that whilst EGFRvIII was not present in normal prostatic glands, the level of expression of this variant protein increased progressively with the gradual transformation of the tissues to the malignant phenotype. The selective association of high EGFRvIII levels with the cancer phenotype underlines the role that this mutant receptor may maintain in the initiation and progression of malignant prostatic growth, and opens the way for new approaches in the management of this disease including gene therapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barlett J, Langdon S, Simpson B, Stewart M, Katsaros D, Simondi P, Love S, Scott W, Williams A, Lessells A, Macleod K, Smyth J and Miller W (1996) The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73: 301–306
Bostwick D, Pacelli A, Blute M, Roche P and Murphy G (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82: 2256–2261
Cohen D, Simark R, Fair W, Melamed J, Scher H and Cordon-Cardo C (1994) Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue. J Urol 152: 2120–2124
Cross M and Dexter T (1991) Growth factors in development, transformation and tumorigenesis (review). Cell 64: 271–280
Davies P, Eaton C, France T and Philips E (1988) Growth factor receptors and oncogene expression in prostatic cell. Am J Clin Oncol Supplement 2: S1–S7
Derynck R, Goeddel D, Ulrich A, Gutterman J, Williams R, Bringman T and Berger W (1993) Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth receptor by human tumours. Cancer Res 47: 707–712
Ekstrand A, Sugawa N, James C and Collins V (1992) Amplified and rearranged epidermal growth factor genes in human glioblastomas reveal deletion sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309–4313
Fong C, Sherwood E, Mendelsohn J, Lee C and Kozlowski J (1992) Epidermal growth facor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumour necrosis factor alpha. Cancer Res 52: 5887–5892
Gleason D, Mellinger G and Group TVACUR (1974) Prediction of prognosis for prostate adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58–64
Glynne-Jones E, Goddard L and Harper M (1996) Comparative analysis of mRNA and protein expression for EGFR and ligands: relationship to proliferative index of human prostate tissue. Hum Pathol 27: 688–696
Greig R, Dunnington D, Murthy U and Mario A (1988) Growth factors as novel therapeutic targets in neoplastic disease. Cancer Surv 7: 644–674
Gullick W (1998) Type 1 growth factor receptors: current status and future work. Biochem Soc Symp 63: 193–198
Haggman M, Macoska J, Wonjo K and Oesterling J (1997) The relationship between prostatic intraepithelial neoplasia and prostate cancer. J Urol 158: 12–22
Humphrey P, Wong A, Vogelstein B, Zalutsky M, Fuller G, Archer G, Friedman H, Kwatra M, Bigner S and Bigner D (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptor in human glioblastoma. Proc Natl Acad Sci USA 87: 4207–4211
Hunts J, Ueda M, Ozawa S, Abe O, Pastan I and Shimuzi N (1985) Hyperproduction and gene amplification of the epidermal growth factor receptor in squamous cell carcinomas. Jpn J Cancer Res 76: 663–666
Kristt D and Yarden Y (1996) Differences between phosphotyrosine accumulation and Neu/Erb-2 receptor expression in astrocytic proliferative processes. Cancer 78: 1272–1283
Laemmli U (1970) Cleavage of structural proteins during the assembly of head bacteriophage. Nature 227: 680–685
Maddy S, Chisholm G, Hawkins R and Habib F (1987) Localisation of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J Endocrinol 113: 147–153
Maddy S, Chisholm G, Busuttil A and Habib F (1989) Epidermal growth factor receptors in prostate cancer: correlation with histological differentiation of the tumour. Br J Cancer 60: 41–44
Maygarden S, Strom S and Ware J (1992) Localisation of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 116: 269–273
Mellon K, Thompson S, Charlton R, Marsh C, Robinson M, Lane D, Harris A, Horne C and Neal D (1992) p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496–499
Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C and Gore M (1996) Phase 1 trial and tumour localisation of the anti-EGFR monoclonal antibody in head and neck or lung cancer. Br J Cancer 73: 228–235
Morris G and Dodd J (1990) Epidermal growth receptor mRNA levels in human prostatic tumour cell lines. J Urology 143: 1272–1274
Moscatello K, Holga-Madruga M, Godwin A, Ramirez G, Gunn G, Zoltick P, Biegel J, Hayes R and Wong A (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 55: 5536–5539
Moscatello D, Montgomery R, Sunderashan P, McDanel H, Wong M and Wong A (1996) Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13: 85–96
Moscatello D, Ramirez G and Wong A (1997) A naturally occurring mutant human epidermal growth factor as a target for peptide vaccine immunotherapy of tumours. Cancer Res 57: 1419–1424
Nagane M, Coufal F, Lin H, Bogler O, Cavenee W and Huang SH-J (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079–5086
Newby J, Johnston S, Smith I and Dowsett M (1997) Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643–1651
Nishakawa R, Ji X-D, Harmon R, Lazar C, Gill G, Cavenee W and Huang H-J (1994) A mutant epidermal growth factor receptor common in human gliomas confers enhanced tumorigencity. Proc Natl Acad Sci USA 91: 7727–7731
Olapade-Olaopa E, MacKay E and Habib F (1998) Variability of immunohistochemical reactivity on stored paraffin slides (letter). J Clin Pathol 51: 943
Olapade-Olaopa E, MacKay E, Taub N, Sandhu D, Terry T and Habib F (1999) Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immuno-reactivity in surrounding stroma. Clin Cancer Res 5: 569–576
Ozanne B, Richards C, Hendler F, Burns D and Gusterson B (1986) Overexpression of the EGF receptor is a hallmark of squamous cell carcinoma. J Pathol 149: 9–14
Panneerselvam K, Kanakaj P, Raj S, Das M and Bishayee S (1995) Characterisation of a novel epidermal-growth-factor-related 200-kDa tyrosine kinase in tumour cells. Eur J Biochem 230: 951–957
Putz T, Culig Z, Eder I, Nessler-Menardi C, Bartsch G, Grunike H, Uberall F and Klocker H (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227–233
Ro J, North S, Gallick G, Hortobagyi G, Gutterman J and Blick M (1988) Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48: 161–164
Sainsbury J, Farndon J, Needham G, Malcom A and Harris A (1987) Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1: 1398–1402
Sakr W and Grigon D (1997) Prostate cancer: indicators of aggressiveness. Eur Urol 32: 15–23
Schmidt M, Reisser P, Hills D, Gullick W and Wels W (1998) Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int J Cancer 75: 878–884
Sherwood E, Dongen JV, Wood C, Liao S, Kozlowski J and Lee C (1998) Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77: 855–861
Thompson D and Gill G (1985) The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 4: 767–788
Tukeri L, Sakr W, Wykes S, Grigon D, Pontes J and Macoska J (1994) Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign and malignant prostate tissue. Prostate 25: 199–205
Ulrich A, Coussens L, Hayflick J, Dull T, Gray A, Tam A, Lee J, Yarden Y, Libermann T, Schlessinger J, Downward J, Maves E, Whittle N, Waterfield M and Seeberg P (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (London) 309: 418–425
Wikstrand C, Hale L, Batra S, Hill M, Humphrey P, Kurpad S, McLendon R, Moscatello D, Pegram C, Reist C, Traweek S, Wong A, Zalutsky M and Bigner D (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140–3148
Wong A, Bigner S, Bigner D, Kinzler K, Hamilton S and Vogelstein B (1987) Increased expression of the EGF receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899–6903
Wong A, Ruppert J, Bigner S, Grzechick C, Humphrey P, Bigner D and Volgstein B (1990) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 87: 4207–4211
Wong A, Ruppert J, Bigner S, Grzeschik C, Humphrey P, Bigner D and Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965–2969
Xu Y, Richert N, Ito S, Merlino G and Pastan I (1984) Characterisation of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 81: 7308–7312
Author information
Authors and Affiliations
Additional information
This project is dedicated to Professor BO Osuntokun (beate memoriae) and Mr PT Doyle (beate memoriae).
These results were presented in part at the Schilling Research Conference, Hormones and Cancer in Santa Cruz, CA, 18–21 September 1997, and the International Symposium of the British Prostate Group in York, UK, 2–4 October 1997.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Olapade-Olaopa, E., Moscatello, D., MacKay, E. et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82, 186–194 (2000). https://doi.org/10.1054/bjoc.1999.0898
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0898
Keywords
This article is cited by
-
Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145
Radiation Oncology (2021)
-
A numerical study on optimising the cryosurgical process for effective tumour necrosis
Heat and Mass Transfer (2017)
-
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
British Journal of Cancer (2012)
-
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation
Oncogene (2010)
-
Targeting non-malignant disorders with tyrosine kinase inhibitors
Nature Reviews Drug Discovery (2010)